期刊
DIGESTIVE AND LIVER DISEASE
卷 48, 期 6, 页码 620-625出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.dld.2016.02.022
关键词
Crohn's disease; Healthcare resource use; Trends; Ulcerative colitis
资金
- Abbvie
- Mayoly Spindler
- Takeda
- Hospira
- Pfizer
- Merck
- Janssen
- Genentech
- Ferring
- Norgine
- Tillots
- Vifor
- Shire
- Therakos
- Pharmacosmos
- Pilege
- BMS
- UCB-Pharma
- Celltrion
- Biogaran
- Boerhinger-Ingelheim
- Lilly
- HAC-Pharma
- Janssen Cilag
- Mitsubishi
Background: Tumour necrosis factor inhibitors (anti-TNFs) are active but expensive drugs that induce and maintain remission in patients with Crohn's disease (CD) and ulcerative colitis (UC). Aims: To assess the trends in anti-TNF prescription and the conditions of prescription of these drugs in patients with inflammatory bowel disease (IBD) in France. Methods: Incidence study of anti-TNF use was performed based on French medico-administrative databases (SNIIRAM/PMSI). IBD patients who initiated adalimumab or infliximab between 2011 and 2013 were selected. Results: The number of new anti-TNF users increased from 4571 to 5875 between 2011 and 2013 (+29%). More specifically, the number of patients not treated with immunosuppressants (IS) during the previous 12 months increased from 2100 to 3007 (+43%), among whom 379 patients in 2011 and 570 patients in 2013 started combination therapy (+50%). These trends were observed for both CD and UC. Patients who were naive of IS were hospitalised more frequently than those treated with IS prior to anti-TNF therapy. Conclusion: This study shows a rapid increase in new prescriptions of anti-TNF for both CD and UC in France between 2011 and 2013. These results suggest a change in medical practices, with anti-TNF agents prescribed more often as first-line maintenance treatment. (C) 2016 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据